Article
Oncology
Sayaka Uda, Tadaaki Yamada, Akihiro Yoshimura, Yasuhiro Goto, Kohei Yoshimine, Yoichi Nakamura, Shinsuke Shiotsu, Takashi Yokoi, Nobuyo Tamiya, Hideharu Kimura, Yusuke Chihara, Yukihiro Umeda, Miiru Izumi, Takayuki Takeda, Takahiro Yamada, Makoto Hibino, Osamu Hiranuma, Kazuhiro Ito, Asuka Okada, Shuji Osugi, Yoshizumi Takemura, Hiroshi Ishii, Kenji Chibana, Isao Hasegawa, Yoshie Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Koichi Takayama
Summary: This study found that in patients with relapsed small cell lung cancer, those who had received different types of topoisomerase inhibitors prior to second-line amrubicin therapy had varying efficacy outcomes, with a significantly longer progression-free survival in the irinotecan group compared to the etoposide group.
TRANSLATIONAL LUNG CANCER RESEARCH
(2022)
Article
Multidisciplinary Sciences
Nathan Farrokhian, Jeff Maltas, Mina Dinh, Arda Durmaz, Patrick Ellsworth, Masahiro Hitomi, Erin McClure, Andriy Marusyk, Artem Kaznatcheev, Jacob G. Scott
Summary: In this study, the frequency-dependent interactions between a gefitinib-resistant non-small cell lung cancer population and its sensitive ancestor were measured experimentally. The cost of resistance was found to be insufficient in predicting competitive exclusion, and frequency-dependent growth rate measurements were necessary. Simulations showed that ecological growth effects can influence the predicted extinction time.
Review
Oncology
Daijiro Harada, Nagio Takigawa
Summary: Retrospective studies support the effectiveness of the strategy of OPD and LAT in treating NSCLC patients with driver mutations, and it is expected to have some effect in patients without driver mutations in certain conditions. After combination therapy of immune checkpoint inhibitors and chemotherapy, LAT with radiotherapy may also have a positive impact.
Article
Oncology
Pasi A. Janne, Christina Baik, Wu-Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A. Yu
Summary: HER3-DXd shows clinical activity in EGFR TKI-resistant lung cancer, regardless of resistance mechanisms, providing a new approach to treat drug-resistant cancers.
Review
Immunology
Miguel Garcia-Pardo, Teresa Gorria, Ines Malenica, Stephanie Corgnac, Cristina Teixido, Laura Mezquita
Summary: Immunotherapy has revolutionized the oncology field and become a new standard of care for NSCLC. However, not all patients benefit from immunotherapy, and there is a need for further strategies to improve outcomes. Therapeutic cancer vaccines have the potential to boost antitumor immunity and work synergistically with immune checkpoint inhibitors. However, current vaccine immunization strategies for lung cancer have been unsuccessful. The success of COVID-19 vaccines raises hope that a similar strategy can be successful in cancer treatment.
Article
Medicine, General & Internal
Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazieres, Misako Nagasaka, Lyudmila Bazhenova, Andreas N. Saltos, Enriqueta Felip, Jose M. Pacheco, Maurice Perol, Luis Paz-Ares, Kapil Saxena, Ryota Shiga, Yingkai Cheng, Suddhasatta Acharyya, Patrik Vitazka, Javad Shahidi, David Planchard, Pasi A. Janne
Summary: Trastuzumab deruxtecan demonstrated durable anticancer activity in previously treated HER2-mutant NSCLC patients, with two cases of fatal drug-related interstitial lung disease reported. The observed toxic effects were generally consistent with previous studies.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Immunology
Yuchang Wang, Rui Chen, Yue Wa, Shikuan Ding, Yijian Yang, Junbo Liao, Lei Tong, Gelei Xiao
Summary: Brain metastasis (BM) is a devastating complication of non-small cell lung cancer (NSCLC). Current main treatment methods for BM carry a high risk of complications. Therefore, immunotherapy based on tumor immune microenvironment has been proposed. The development of NSCLC and its BM is closely related to the tumor microenvironment. Immune checkpoint inhibition therapy plays a crucial role in targeting immune-related cells and chemicals in the BM microenvironment. Immunotherapy has shown significant advances in treating BM with a higher safety profile.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Hiroki Izumi, Shingo Matsumoto, Jie Liu, Kosuke Tanaka, Shunta Mori, Kumiko Hayashi, Shogo Kumagai, Yuji Shibata, Takuma Hayashida, Kana Watanabe, Tatsuro Fukuhara, Takaya Ikeda, Kiyotaka Yoh, Terufumi Kato, Kazumi Nishino, Atsushi Nakamura, Ichiro Nakachi, Shoichi Kuyama, Naoki Furuya, Jun Sakakibara-Konishi, Isamu Okamoto, Kageaki Taima, Noriyuki Ebi, Haruko Daga, Akira Yamasaki, Masahiro Kodani, Hibiki Udagawa, Keisuke Kirita, Yoshitaka Zenke, Kaname Nosaki, Eri Sugiyama, Tetsuya Sakai, Tokiko Nakai, Genichiro Ishii, Seiji Niho, Atsushi Ohtsu, Susumu S. Kobayashi, Koichi Goto
Summary: Lung cancer is a highly aggressive tumor type, and targeted therapies based on oncogenic drivers have greatly improved outcomes for patients with non-small-cell lung cancer (NSCLC). However, a significant percentage of lung adenocarcinoma cases lack known oncogenic drivers, and the identification of the CLIP1-LTK fusion as a potential target in NSCLC represents a novel finding with therapeutic implications.
Article
Cell Biology
Kathryn Davidson, Paul Grevitt, Maria F. Contreras-Gerenas, Katherine S. Bridge, Miguel Hermida, Kunal M. Shah, Faraz K. Mardakheh, Mark Stubbs, Rosemary Burke, Pedro Casado, Pedro R. Cutillas, Sarah A. Martin, Tyson Sharp
Summary: The loss of the tumour suppressor gene LIMD1 is an early event in lung oncogenesis, affecting approximately 45% of non-small cell lung cancers. A drug repurposing screen identified PF-477736 as selectively targeting LIMD1-deficient cells, inducing cell death through apoptosis. PF-477736 showed effectiveness in treating LIMD1(-/-) tumors in xenograft models, presenting a potential new therapeutic subgroup for critical unmet needs.
CELL DEATH & DISEASE
(2021)
Article
Oncology
Kohei Kushiro, Satoshi Watanabe, Yuka Goto, Toshiya Fujisaki, Naohiro Yanagimura, Aya Ohtsubo, Satoshi Shoji, Koichiro Nozaki, Tomohiro Tanaka, Yu Saida, Yusuke Sato, Takeshi Ota, Jun Koshio, Yoshiki Hayashi, Takao Miyabayashi, Naoya Matsumoto, Kosuke Ichikawa, Kenichi Koyama, Toshiaki Kikuchi
Summary: This retrospective study evaluated the efficacy and safety of amrubicin (AMR) therapy in patients with recurrent SCLC after chemoimmunotherapy. Results showed that AMR demonstrated good clinical efficacy and safety, with median PFS and OS of 3.8 months and 10 months, respectively. Grade & GE;3 neutropenia was the most common adverse event, occurring in 73% of patients.
TRANSLATIONAL LUNG CANCER RESEARCH
(2022)
Review
Oncology
Leylah M. Drusbosky, Richa Dawar, Estelamari Rodriguez, Chukwuemeka Ikpeazu
Summary: The MET exon 14 skipping mutation is present in a small percentage of lung cancer patients, but targeted inhibitors like capmatinib and tepotinib show promising clinical activity with tolerable toxicity profiles. Ongoing research aims to overcome acquired resistance and enhance the effectiveness of these agents.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Pharmacology & Pharmacy
Tao Yang, Yilin Xiong, Yufei Zeng, Yan Wang, Jing Zeng, Jie Liu, Shangfu Xu, Li-Sheng Li
Summary: Lung cancer, especially non-small cell lung cancer (NSCLC), is still the leading cause of cancer-related deaths worldwide. Despite some clinical advancements in conventional treatments, the survival rate of NSCLC remains low. In recent years, immunotherapy, including antibody therapy and cell therapy, has emerged as a new frontier in lung cancer research, particularly immune checkpoint inhibitors (ICI). These approaches have significantly improved the survival rate and treatment response in NSCLC patients by enhancing the immune system and targeting tumor cells more effectively. This paper provides a comprehensive review of the relevant targets, clinical progress, and adverse reactions of various immunotherapies, as well as their combination therapies, aiming to offer better treatment options for NSCLC.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Cell Biology
Tong Zhou, Yong-Hua Sang, Shang Cai, Chun Xu, Min-hua Shi
Summary: POLRMT is overexpressed in NSCLC and plays a crucial role in cell proliferation, migration, and apoptosis. Silencing or knockout of POLRMT inhibits NSCLC cell growth, while overexpression of POLRMT enhances cell proliferation and migration. Regulation of mtDNA content, mRNA levels of mitochondrial transcripts, and respiratory chain complex subunits contribute to the growth of NSCLC.
CELL DEATH & DISEASE
(2021)
Article
Oncology
Yasir Y. Elamin, Jacqulyne P. Robichaux, Brett W. Carter, Mehmet Altan, Don L. Gibbons, Frank Fossella, Vincent K. Lam, Anisha B. Patel, Marcelo Negrao, Xiuning Le, Frank E. Mott, Jianjun Zhang, Lei Feng, George Blumenschein, Anne S. Tsao, John Heymach
Summary: Poziotinib demonstrated promising antitumor activity in patients with HER2 exon 20 mutant NSCLC, including those who had previously received platinum-based chemotherapy.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Noriaki Sunaga, Yosuke Miura, Norimitsu Kasahara, Reiko Sakurai
Summary: The v-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS) is the most common driver in non-small-cell lung cancer (NSCLC), making targeting KRAS crucial for treatment. While the discovery of covalent KRAS G12C inhibitors offers hope for improving NSCLC patient prognosis, developing combination therapies tailored to tumor characteristics is still necessary given the vast heterogeneity of KRAS-mutated NSCLC.
